menu
    • menu

    Company profile for Lycera

    NEW Drugs in Dev: 3
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Lycera is a private biopharmaceutical company that is developing novel small molecule immunomodulatory medicines for the treatment of autoimmune diseases and cancer. Based on its world-class R&D engine, Lycera is advancing clinical candidates from distinct, yet complementary, areas of research, including immune metabolism, cell signaling, and immune cell differentiation. The Company has a leading position in the development...
    Lycera is a private biopharmaceutical company that is developing novel small molecule immunomodulatory medicines for the treatment of autoimmune diseases and cancer. Based on its world-class R&D engine, Lycera is advancing clinical candidates from distinct, yet complementary, areas of research, including immune metabolism, cell signaling, and immune cell differentiation. The Company has a leading position in the development of agonists of RORγ, a master transcription factor, or “master control switch,” with diverse applications in immuno-oncology.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    LyceraUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1350 Highland Drive Suite A Ann Arbor, MI 48108
    Telephone
    Telephone
    +734 233 3060
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://lycera.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/lycera/?originalSubdomain=in
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lycera Presents Clinical Safety & Selection Results RORgamma Agonist LYC-55716
    Lycera Presents Clinical Safety & Selection Results RORgamma Agonist LYC-55716

    17 Apr 2018

    // PRESS RELEASE

    https://lycera.com/press/lycera-presents-clinical-safety-dose-selection-results-first-class-rorgamma-agonist-candidate-lyc-55716-2018-aacr-annual-meeting

    PRESS RELEASE
    17 Apr 2018
    Share Share
    Lycera to Present Clinical Results & Supporting Preclinical Data
    Lycera to Present Clinical Results & Supporting Preclinical Data

    17 Apr 2018

    // PRESS RELEASE

    https://lycera.com/press/lycera-present-clinical-results-supporting-preclinical-data-first-class-rorgamma-agonist-lyc-55716-2018-aacr-annual-meeting

    PRESS RELEASE
    17 Apr 2018
    Share Share
    Lycera to Present on First-in-class RORgamma Agonist Candidate LYC-55716
    Lycera to Present on First-in-class RORgamma Agonist Candidate LYC-55716

    30 Mar 2018

    //

    https://lycera.com/press/lycera-present-first-class-rorgamma-agonist-candidate-lyc-55716-2018-asco-annual-meeting

    30 Mar 2018
    Share Share
    Lycera Announces Publication of Preclinical Immuno-Oncology Research
    Lycera Announces Publication of Preclinical Immuno-Oncology Research

    16 Mar 2018

    // PRESS RELEASE

    https://lycera.com/press/lycera-announces-publication-preclinical-immuno-oncology-research-demonstrating-treatment-rorgamma-agonists-enhances-car-t-cell-anti-tumor-activity-persistence-resulting-long-las

    PRESS RELEASE
    16 Mar 2018
    Share Share
    Lycera Announces Initiation of Phase 1b LYC-55716 in Combination Pembrolizumab
    Lycera Announces Initiation of Phase 1b LYC-55716 in Combination Pembrolizumab

    04 Jan 2018

    // PRESS RELEASE

    https://lycera.com/press/lycera-announces-initiation-phase-1b-study-novel-immuno-oncology-candidate-lyc-55716-combination-pembrolizumab

    PRESS RELEASE
    04 Jan 2018
    Share Share
    Lycera Announces Advancement of Novel Immuno-Oncology Candidate LYC-55716
    Lycera Announces Advancement of Novel Immuno-Oncology Candidate LYC-55716

    19 Oct 2017

    // PRESS RELEASE

    https://lycera.com/press/lycera-announces-advancement-of-novel-immuno-oncology-candidate-lyc-55716-rorgamma-agonist-into-phase-2a

    PRESS RELEASE
    19 Oct 2017
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search